2,2-dimethyl-heptan-4-one | 1762-19-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2,2-dimethyl-heptan-4-one
• 英文别名: 2,2-Dimethyl-heptan-4-on；Propyl-neopentyl-keton；2,2-Dimethylheptan-4-one
• CAS: 1762-19-2
• 化学式: C₉H₁₈O
• 分子量: 142.241
• InChiKey: JUQWYDYXUFYJNR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2,2-dimethyl-heptan-4-one 生成 phenyl-carbamic acid-(3,3-dimethyl-1-propyl-butyl ester)
  参考文献：
  名称：

  The Action of Primary Grignard Reagents on t-Butylacetyl Chloride

  摘要：

  DOI：

  10.1021/ja01277a048
• 作为产物：
  描述：

  6,6-Dimethyl-2,4-heptadiin 在 Lindlar's catalyst 硫酸 、 氢气 作用下， 以 甲醇 为溶剂， 生成 2,2-dimethyl-heptan-4-one
  参考文献：
  名称：

  Turbanova,E.S. et al., Journal of Organic Chemistry USSR (English Translation), 1966, vol. 2, p. 775 - 779

  摘要：

  DOI：

文献信息

• PYRROLIDINYL SULFONE RORGAMMA MODULATORS
  申请人：Bristol-Myers Squibb Company

  公开号：US20150191483A1

  公开（公告）日：2015-07-09

  Described are RORγ modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORγ activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORγ activity, for example, autoimmune and/or inflammatory disorders.

  描述了公式（I）的RORγ调节剂，或其立体异构体、互变异构体、药物可接受的盐、溶剂化物或前药，其中所有取代基都在此定义。还提供了包含相同成分的药物组合物。这类化合物和组合物在调节细胞中RORγ活性的方法和治疗受疾病或紊乱困扰的主体中是有用的，例如，主体将从调节RORγ活性中获益的自免疫和/或炎症紊乱。
• Benzothiazole Kinase Inhibitors and Methods of Use
  申请人：Intellikine LLC

  公开号：US20150225407A1

  公开（公告）日：2015-08-13

  The present invention provides chemical entities or compounds and pharmaceutical compositions thereof that are capable of modulating lipid kinases such PI3 kinases, tryosine kinases and protein kinases such as mTOR. Also provided in the present invention are methods of using these compositions to modulate these kinases especially for therapeutic applications.

  本发明提供了能够调节脂质激酶如PI3激酶、酪氨酸激酶和蛋白激酶如mTOR的化学实体或化合物以及其药物组合物。本发明还提供了使用这些组合物来调节这些激酶的方法，特别是用于治疗应用。
• Crystalline forms of almotriptan and processes for their preparation
  申请人：Sridharan Ramasubramanian

  公开号：US20070112055A1

  公开（公告）日：2007-05-17

  Crystalline forms of almotriptan and almotriptan malate are disclosed. Processes for their preparation and pharmaceutical compositions containing the same are also disclosed. The amorphous form of almotriptan malate, processes for its preparation and a pharmaceutical composition containing the same are also disclosed

  揭示了almotriptan和almotriptan malate的结晶形式。还揭示了它们的制备过程和含有它们的药物组合物。此外，还揭示了almotriptan malate的非晶形式，其制备过程以及含有它的药物组合物。
• Rate controlled release of a pharmaceutical agent in a biodegradable device
  申请人：Kunzler Jay

  公开号：US20070218103A1

  公开（公告）日：2007-09-20

  Matrix controlled diffusion drug delivery systems comprising a therapeutically effective amount of one or more pharmaceutically active agents entrapped in a copolymer which is a reaction product of a monomeric mixture comprising one or more acrylate ester and/or methacrylate ester-containing monomers and one or more acrylamido-containing monomers are disclosed. Also disclosed are processes for their preparations and methods for their use.

  本发明揭示了矩阵控制扩散药物传递系统，其中包括一种或多种药物活性剂的治疗有效量，这些活性剂被困在共聚物中，该共聚物是由单体混合物反应生成的，该单体混合物包括一种或多种丙烯酸酯和/或甲基丙烯酸酯含有单体和一种或多种丙烯酰胺含有单体。还揭示了其制备过程和使用方法。
• Process for the purification of fluconazole
  申请人：Chandrasekhar Batchu

  公开号：US20050282878A1

  公开（公告）日：2005-12-22

  The present invention relates to processes for the purification of crude fluconazole including at least a first leaching, a second leaching, and an acid/base treatment and to highly purified fluconazole produced from the processes.

  本发明涉及粗氟康唑的纯化过程，包括至少一次第一浸提、第二次浸提和酸/碱处理，并涉及由该过程生产的高纯度氟康唑。